Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OPKO Health, Inc. (OPK)
USD1.22
-0.01 (-0.41%)
US NASDAQ Healthcare Biotechnology
Address
4400 Biscayne Boulevard 33137
Miami, FL, US
Miami, FL, US
CEO
Phillip Frost
Website
opko.com
IPO
1995-11-02
CIK 944809 ISIN US68375N1037
Also trades on
London Stock Exchange · 0KCS.L (USD)
NASDAQ Global Select · OPK (USD)
Tel Aviv Stock Exchange · OPK.TA (ILA)
Description
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
Market Cap & Enterprise Value
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.22
-0.01 (-0.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.49
Float Shares
332.68M
Free Float %
44.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.10% | +14.96% | +29.20% | +21.67% | +7.35% | +15.87% | +5.80% | +5.04% | -59.56% | -86.27% | -67.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
1.22
Low
1.60
+31.7%
Consensus
2.87
+136.2%
Median
3.00
+146.9%
High
4.00
+229.2%
DCF (Unlevered)
0.10
-91.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
63% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
1.60
+31.7%
|
| All Time | 4 |
2.90
+138.7%
|
Quality scores
Altman Z-Score
-0.67
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-14.9% Q1'26: -17.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-291.1% Q1'26: +27.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-45.1% Q1'26: -17.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-36.1% Q1'26: -41.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-16.4% Q1'26: -14.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.2% Q1'26: +13.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.40× Q1'26: -3.44× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
91.10M
est: 98.50M (-7.5%)
|
491.70M
est: 502.11M (-2.1%)
|
1.22B
est: 1.25B (-2.0%)
|
966.01M
est: 1.18B (-18.3%)
|
990.30M
est: 1.01B (-2.3%)
|
901.94M
est: 893.70M (+0.9%)
|
1.44B
est: 1.38B (+4.0%)
|
1.77B
est: 1.70B (+4.2%)
|
1.00B
est: 986.82M (+1.8%)
|
863.50M
est: 716.37M (+20.5%)
|
713.14M
est: 684.92M (+4.1%)
|
606.88M
est: 598.10M (+1.5%)
|
537.77M
530.61M – 548.03M
-10.1% YoY
|
567.70M
552.72M – 580.96M
+5.6% YoY
|
609.00M
608.95M – 609.05M
+7.3% YoY
|
649.70M
627.90M – 665.21M
+6.7% YoY
|
690.05M
666.90M – 706.53M
+6.2% YoY
|
| EBITDA |
-143.84M
est: -129.94M (-10.7%)
|
-87.33M
est: -10.3K (-848,268.0%)
|
7.18M
est: -25.6K (+28,199.8%)
|
-163.23M
est: -24.2K (-673,041.2%)
|
-68.04M
est: -48.30M (-40.8%)
|
-189.64M
est: -202.61M (+6.4%)
|
155.98M
est: 235.00M (-33.6%)
|
83.57M
est: 261.69M (-68.1%)
|
-270.81M
est: -649.77M (+58.3%)
|
-65.52M
est: -45.65M (-43.5%)
|
135.28M
est: -43.65M (+409.9%)
|
-127.36M
est: -38.11M (-234.1%)
|
-34.27M
-34.92M – -33.81M
+10.1% YoY
|
-36.18M
-37.02M – -35.22M
-5.6% YoY
|
-38.81M
-38.81M – -38.81M
-7.3% YoY
|
-41.40M
-42.39M – -40.01M
-6.7% YoY
|
-43.97M
-45.02M – -42.50M
-6.2% YoY
|
| EBIT |
-158.76M
est: -134.51M (-18.0%)
|
-129.58M
est: -47.37M (-173.5%)
|
-89.39M
est: -117.65M (+24.0%)
|
-265.32M
est: -111.59M (-137.8%)
|
-165.38M
est: -168.56M (+1.9%)
|
-283.45M
est: -287.42M (+1.4%)
|
70.62M
est: 84.59M (-16.5%)
|
4.86M
est: 61.53M (-92.1%)
|
-379.47M
est: -196.82M (-92.8%)
|
-170.81M
est: -126.34M (-35.2%)
|
37.10M
est: -120.79M (+130.7%)
|
-218.99M
est: -105.48M (-107.6%)
|
-94.84M
-96.65M – -93.58M
+10.1% YoY
|
-100.12M
-102.45M – -97.48M
-5.6% YoY
|
-107.40M
-107.41M – -107.39M
-7.3% YoY
|
-114.58M
-117.31M – -110.73M
-6.7% YoY
|
-121.69M
-124.60M – -117.61M
-6.2% YoY
|
| Net Income |
-171.67M
est: -156.98M (-9.4%)
|
-30.03M
est: -48.58M (+38.2%)
|
-48.36M
est: -52.75M (+8.3%)
|
-305.25M
est: -181.31M (-68.4%)
|
-153.04M
est: -154.57M (+1.0%)
|
-314.93M
est: -321.48M (+2.0%)
|
30.59M
est: 71.14M (-57.0%)
|
-30.14M
est: -97.11M (+69.0%)
|
-328.41M
est: -209.23M (-57.0%)
|
-188.86M
est: -243.10M (+22.3%)
|
-53.22M
est: -177.14M (+70.0%)
|
-225.68M
est: -279.37M (+19.2%)
|
-229.27M
-277.14M – -197.95M
+17.9% YoY
|
-195.06M
-253.28M – -136.91M
+14.9% YoY
|
-48.47M
-142.81M – 127.8K
+75.1% YoY
|
-75.11M
-77.44M – -71.84M
-55.0% YoY
|
-60.09M
-61.96M – -57.47M
+20.0% YoY
|
| SGA |
57.94M
est: 56.63M (+2.3%)
|
196.58M
est: 166.47M (+18.1%)
|
490.90M
est: 413.42M (+18.7%)
|
414.63M
est: 392.12M (+5.7%)
|
358.40M
est: 446.94M (-19.8%)
|
343.31M
est: 324.38M (+5.8%)
|
355.57M
est: 442.26M (-19.6%)
|
468.86M
est: 1.47B (-68.1%)
|
372.67M
est: 327.17M (+13.9%)
|
300.56M
est: 254.66M (+18.0%)
|
304.22M
est: 243.48M (+24.9%)
|
223.00M
est: 212.62M (+4.9%)
|
191.17M
188.63M – 194.82M
-10.1% YoY
|
201.81M
196.48M – 206.52M
+5.6% YoY
|
216.49M
216.47M – 216.51M
+7.3% YoY
|
230.96M
223.21M – 236.47M
+6.7% YoY
|
245.30M
237.07M – 251.16M
+6.2% YoY
|
| EPS |
-0.41
est: -0.32 (-30.2%)
|
-0.06
est: -0.07 (+12.1%)
|
-0.05
est: -0.08 (+34.2%)
|
-0.55
est: -0.26 (-110.5%)
|
-0.27
est: -0.23 (-19.1%)
|
-0.53
est: -0.44 (-21.8%)
|
0.05
est: 0.03 (+83.5%)
|
-0.05
est: 0.04 (-203.4%)
|
-0.46
est: -0.44 (-4.2%)
|
-0.25
est: -0.33 (+25.2%)
|
-0.08
est: -0.18 (+57.4%)
|
-0.30
est: -0.35 (+13.6%)
|
-0.31
-0.37 – -0.26
+11.9% YoY
|
-0.26
-0.34 – -0.18
+13.5% YoY
|
-0.09
-0.19 – 0.00
+65.9% YoY
|
-0.10
-0.10 – -0.10
-11.1% YoY
|
-0.08
-0.08 – -0.08
+20.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | Barrington Research | Outperform | Market Perform | Downgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-188.74M
OE per share TTM
-0.24
Owner's Yield
-17.03%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
235
Total invested
228.97M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David Rosen | 48.71M | 6.98% | — | 48.71M | — | — | IN | United States of America | 2024-11-13 | ↗ |
| 2 | Rubric Capital Management LP | 48.71M | 6.98% | — | 48.71M | — | — | IA, PN | United States of America | 2024-11-13 | ↗ |
| 3 | Bruce C. Holbrook | 39.78M | 5.80% | 226.1K | 39.56M | 226.1K | 39.56M | IN | — | 2022-06-29 | ↗ |
| 4 | Coe M. Magruder | 39.72M | 5.80% | — | 39.72M | — | 39.72M | IN | — | 2022-06-29 | ↗ |
| 5 | (1)Names of reporting persons. BlackRock, Inc. | 36.12M | 5.40% | 34.97M | — | 36.12M | — | HC | Delaware | 2020-02-07 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 35.73M | 5.24% | — | 337.8K | 35.02M | 710.4K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 7 | Jane Hsiao, Ph.D. | 35.01M | 5.20% | 35.01M | — | 35.01M | — | IN | — | 2020-03-20 | ↗ |
| 8 | (1) BlackRock, Inc. | 33.97M | 4.98% | 32.54M | — | 33.97M | — | HC | Delaware | 2022-03-09 | ↗ |
| 9 | Gary J. Nabel, M.D., Ph.D. | 20.01M | 2.90% | 155.5K | 19.86M | 155.5K | 19.86M | IN | — | 2022-06-29 | ↗ |
| 10 | Elizabeth G. Nabel, M.D. | 19.97M | 2.90% | 113.2K | 19.86M | 113.2K | 19.86M | IN | — | 2022-06-29 | ↗ |
| 11 | Elias A. Zerhouni, M.D. | 19.87M | 2.90% | 89.6K | 19.78M | 89.6K | 19.78M | IN | — | 2022-06-29 | ↗ |
| 12 | EGN 2021 Trust | 19.86M | 2.90% | — | 19.86M | — | 19.86M | OO | — | 2022-06-29 | ↗ |
| 13 | GJN 2021 Trust | 19.86M | 2.90% | — | 19.86M | — | 19.86M | OO | — | 2022-06-29 | ↗ |
| 14 | EAZ Zeraz Trust | 19.78M | 2.90% | — | 19.78M | — | 19.78M | OO | — | 2022-06-29 | ↗ |
| 15 | Zerhouni Irrevocable Trust | 19.78M | 2.90% | — | 19.78M | — | 19.78M | OO | — | 2022-06-29 | ↗ |
| 16 | Inc. Fed. Id. 75-2402409 | 19.44M | 51.90% | — | 19.44M | — | 10.00 | CO | Delaware | 2007-02-16 | ↗ |
| 17 | Hsu Gamma Investment, L.P. | 5.13M | 0.80% | 5.13M | — | 5.13M | — | PN | — | 2020-03-20 | ↗ |
| 18 | 75-2402409 | 5.06M | 9.90% | 5.06M | — | 5.06M | — | CO | Delaware | 2018-02-14 | ↗ |
| 19 | NEW VALLEY LLC | 2.26M | 6.20% | — | — | — | — | CO | : | 2007-02-13 | ↗ |
| 20 | OPKO Health, Inc. | 2.17M | 8.06% | — | — | — | — | CO | — | 2024-09-18 | ↗ |
| 21 | 4.99% (2) | 488.1K | 4.99% | 488.1K | — | 488.1K | — | CO | Delaware | 2019-05-09 | ↗ |
| 22 | 4.99% (1) | 487.9K | 4.99% | — | 487.9K | — | 487.9K | IN | Delaware | 2019-05-09 | ↗ |
| 23 | (2) | 446.4K | 5.11% | 446.4K | — | 446.4K | — | CO | Delaware | 2017-01-12 | ↗ |
| 24 | Nabel Family Investments LLC | 80.0K | 0.01% | 80.0K | — | 80.0K | — | OO | — | 2022-06-29 | ↗ |
| 25 | Marsh & McLennan Companies, Inc. | — | 0.00% | 2.26M | — | 2.26M | — | HC | Delaware | 2016-08-22 | ↗ |
| 26 | VECTOR GROUP LTD. | — | 0.00% | — | — | — | — | HC, CO | : | 2007-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
235
+10 vs prev Q
New positions
45
Closed positions
32
Increased
104
Reduced
59
Put/Call ratio
0.40
Calls held
151.0K
Puts held
60.4K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RUBRIC CAPITAL MANAGEMENT LP | 47.79M +— (+0.0%) | 60.22M -13.9M (-18.7%) | 6.15% -0.967 pp | 0.72% -0.116 pp | USD1.26 +0.0% | 8 qtrs — |
| 2 | BLACKROCK, INC. | 34.85M +1.7M (+5.1%) | 43.91M -7.5M (-14.6%) | 4.48% -0.455 pp | 0.00% 0.000 pp | USD1.46 -13.7% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 32.46M -5.1M (-13.5%) | 40.90M -17.3M (-29.7%) | 4.18% -1.413 pp | 0.00% 0.000 pp | USD4.21 -70.1% | 74 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 11.06M +68.0K (+0.6%) | 13.94M -3.1M (-18.2%) | 1.42% -0.214 pp | 0.00% 0.000 pp | USD3.56 -64.6% | 66 qtrs — |
| 5 | STATE STREET CORP | 8.95M -46.2K (-0.5%) | 11.28M -2.7M (-19.1%) | 1.15% -0.188 pp | 0.00% 0.000 pp | USD3.10 -59.4% | 51 qtrs — |
| 6 | GOLDMAN SACHS GROUP INC | 5.99M +3.6M (+150.9%) | 7.54M +3.8M (+103.9%) | 0.77% +0.415 pp | 0.00% +0.001 pp | USD1.70 -25.9% | 61 qtrs — |
| 7 | UBS GROUP AG | 5.35M +577.2K (+12.1%) | 6.74M -657.6K (-8.9%) | 0.69% -0.022 pp | 0.00% 0.000 pp | USD1.39 -9.4% | 45 qtrs — |
| 8 | WHITEFORT CAPITAL MANAGEMENT, LP | 4.25M -646.7K (-13.2%) | 5.36M -2.2M (-29.4%) | 0.55% -0.182 pp | 1.37% -0.875 pp | USD1.47 -14.3% | 7 qtrs — |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.69M -76.3K (-2.0%) | 4.65M -1.2M (-20.4%) | 0.48% -0.086 pp | 0.00% 0.000 pp | USD3.07 -59.0% | 64 qtrs — |
| 10 | NORTHERN TRUST CORP | 3.44M -219.5K (-6.0%) | 4.33M -1.3M (-23.6%) | 0.44% -0.102 pp | 0.00% 0.000 pp | USD3.66 -65.6% | 51 qtrs — |
| 11 | CITADEL ADVISORS LLC | 2.86M +2.6M (+921.0%) | 3.60M +3.2M (+729.9%) | 0.37% +0.326 pp | 0.00% +0.001 pp | USD1.29 -2.3% | 52 qtrs — |
| 12 | AWM INVESTMENT COMPANY, INC. | 2.10M -100.0K (-4.5%) | 2.65M -764.0K (-22.4%) | 0.27% -0.057 pp | 0.26% -0.064 pp | USD2.19 -42.5% | 45 qtrs — |
| 13 | AQR CAPITAL MANAGEMENT LLC | 2.03M -846.5K (-29.5%) | 2.55M -1.9M (-42.7%) | 0.26% -0.167 pp | 0.00% -0.002 pp | USD1.58 -20.3% | 22 qtrs — |
| 14 | JANE STREET GROUP, LLC | 1.78M +1.5M (+575.4%) | 2.24M +1.8M (+449.1%) | 0.23% +0.189 pp | 0.00% +0.000 pp | USD1.28 -1.6% | 48 qtrs — |
| 15 | DIMENSIONAL FUND ADVISORS LP | 1.61M -56.1K (-3.4%) | 2.03M -550.8K (-21.3%) | 0.21% -0.041 pp | 0.00% 0.000 pp | USD3.50 -64.0% | 51 qtrs — |
| 16 | WASHINGTON GROWTH STRATEGIES LLC | 1.36M +— (+0.0%) | 1.71M -393.3K (-18.7%) | 0.17% -0.027 pp | 1.10% -0.394 pp | USD1.32 -4.5% | 4 qtrs — |
| 17 | Y.D. MORE INVESTMENTS LTD | 1.31M -192.7K (-12.9%) | 1.67M -564.6K (-25.3%) | 0.17% -0.055 pp | 0.08% -0.046 pp | USD1.35 -6.7% | 7 qtrs — |
| 18 | PFG INVESTMENTS, LLC | 1.32M -17.0K (-1.3%) | 1.66M -409.2K (-19.7%) | 0.17% -0.029 pp | 0.08% -0.029 pp | USD1.36 -7.4% | 8 qtrs — |
| 19 | BANK OF NEW YORK MELLON CORP | 1.31M +33.2K (+2.6%) | 1.65M -328.4K (-16.6%) | 0.17% -0.022 pp | 0.00% 0.000 pp | USD4.43 -71.6% | 66 qtrs — |
| 20 | VOYA INVESTMENT MANAGEMENT LLC | 1.10M -115.8K (-9.5%) | 1.39M -499.2K (-26.4%) | 0.14% -0.040 pp | 0.00% -0.001 pp | USD1.61 -21.7% | 51 qtrs — |
| 21 | MORGAN STANLEY | 917.4K +79.8K (+9.5%) | 1.16M -142.4K (-11.0%) | 0.12% -0.007 pp | 0.00% +0.000 pp | USD1.70 -25.9% | 51 qtrs — |
| 22 | CLEARSTEAD ADVISORS, LLC | 882.4K +882.4K (+100.0%) | 1.11M +1.1M (+100.0%) | 0.11% +0.114 pp | 0.01% +0.014 pp | USD1.26 +0.0% | 7 qtrs — |
| 23 | TEJARA CAPITAL LTD | 877.9K +— (+0.0%) | 1.11M -254.6K (-18.7%) | 0.11% -0.018 pp | 0.26% -0.450 pp | USD1.30 -3.1% | 7 qtrs — |
| 24 | SWISS NATIONAL BANK | 845.8K +— (+0.0%) | 1.07M -245.3K (-18.7%) | 0.11% -0.017 pp | 0.00% 0.000 pp | USD4.19 -69.9% | 51 qtrs — |
| 25 | NUVEEN, LLC | 841.8K +— (+0.0%) | 1.06M -244.1K (-18.7%) | 0.11% -0.017 pp | 0.00% 0.000 pp | USD1.66 -24.1% | 4 qtrs — |
| 26 | INVESCO LTD. | 781.7K -235.9K (-23.2%) | 984.9K -592.3K (-37.6%) | 0.10% -0.051 pp | 0.00% 0.000 pp | USD1.37 -8.0% | 56 qtrs — |
| 27 | TWO SIGMA INVESTMENTS, LP | 734.7K -520.9K (-41.5%) | 925.8K -1.0M (-52.4%) | 0.09% -0.092 pp | 0.00% -0.002 pp | USD1.59 -20.8% | 15 qtrs — |
| 28 | HRT FINANCIAL LP | 675.5K +675.5K (+100.0%) | 851.0K +851.0K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.003 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 29 | UBS ASSET MANAGEMENT AMERICAS INC | 673.6K +— (+0.0%) | 848.7K -195.3K (-18.7%) | 0.09% -0.014 pp | 0.00% +0.000 pp | USD2.14 -41.1% | 52 qtrs — |
| 30 | BARCLAYS PLC | 663.2K +119.9K (+22.1%) | 835.7K +26.1K (+3.2%) | 0.09% +0.004 pp | 0.00% +0.000 pp | USD1.39 -9.4% | 51 qtrs — |
| 31 | ASSENAGON ASSET MANAGEMENT S.A. | 652.1K -38.1K (-5.5%) | 834.7K -195.3K (-19.0%) | 0.08% -0.019 pp | 0.00% 0.000 pp | USD1.46 -13.7% | 12 qtrs — |
| 32 | COMMONWEALTH EQUITY SERVICES, LLC | 641.5K +49.1K (+8.3%) | 808.2K -109.8K (-12.0%) | 0.08% -0.006 pp | 0.00% 0.000 pp | USD1.35 -6.7% | 8 qtrs — |
| 33 | GSA CAPITAL PARTNERS LLP | 621.3K +621.3K (+100.0%) | 783.0K +783.0K (+100.0%) | 0.08% +0.080 pp | 0.07% +0.068 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 34 | BANK OF AMERICA CORP /DE/ | 618.3K -695.6K (-52.9%) | 779.0K -1.3M (-61.7%) | 0.08% -0.116 pp | 0.00% 0.000 pp | USD1.64 -23.2% | 52 qtrs — |
| 35 | JPMORGAN CHASE & CO | 579.8K +52.4K (+9.9%) | 730.5K -87.0K (-10.6%) | 0.07% -0.004 pp | 0.00% +0.000 pp | USD2.13 -40.8% | 42 qtrs — |
| 36 | RHUMBLINE ADVISERS | 511.5K -43.9K (-7.9%) | 644.5K -216.4K (-25.1%) | 0.07% -0.017 pp | 0.00% 0.000 pp | USD4.18 -69.9% | 51 qtrs — |
| 37 | WELLS FARGO & COMPANY/MN | 468.5K +126.0K (+36.8%) | 590.3K +59.5K (+11.2%) | 0.06% +0.009 pp | 0.00% +0.000 pp | USD1.71 -26.3% | 57 qtrs — |
| 38 | LEGAL & GENERAL GROUP PLC | 453.3K +66.4K (+17.2%) | 571.1K -27.1K (-4.5%) | 0.06% +0.001 pp | 0.00% +0.000 pp | USD3.05 -58.7% | 46 qtrs — |
| 39 | ALLIANCEBERNSTEIN L.P. | 448.2K -27.0K (-5.7%) | 564.7K -171.8K (-23.3%) | 0.06% -0.013 pp | 0.00% 0.000 pp | USD3.13 -59.7% | 61 qtrs — |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 437.3K +139.5K (+46.8%) | 551.0K +89.3K (+19.4%) | 0.06% +0.012 pp | 0.00% +0.000 pp | USD1.54 -18.2% | 51 qtrs — |
| 41 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 430.6K +37.9K (+9.6%) | 542.6K -66.2K (-10.9%) | 0.06% -0.003 pp | 0.00% -0.001 pp | USD1.46 -13.7% | 5 qtrs — |
| 42 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 417.1K +1.7K (+0.4%) | 525.5K -118.3K (-18.4%) | 0.05% -0.008 pp | 0.00% 0.000 pp | USD5.70 -77.9% | 52 qtrs — |
| 43 | TWO SIGMA SECURITIES, LLC | 374.5K +253.4K (+209.2%) | 471.8K +284.1K (+151.4%) | 0.05% +0.030 pp | 0.06% +0.037 pp | USD1.35 -6.7% | 13 qtrs — |
| 44 | PRICE T ROWE ASSOCIATES INC /MD/ | 367.2K +23.9K (+7.0%) | 463.0K -70.0K (-13.1%) | 0.05% -0.004 pp | 0.00% +0.000 pp | USD2.49 -49.4% | 69 qtrs — |
| 45 | XTX TOPCO LTD | 342.8K +342.8K (+100.0%) | 431.9K +431.9K (+100.0%) | 0.04% +0.044 pp | 0.01% +0.011 pp | USD1.26 +0.0% | 11 qtrs — |
| 46 | DEUTSCHE BANK AG\ | 325.9K +50.7K (+18.4%) | 410.6K -15.9K (-3.7%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD1.54 -18.2% | 50 qtrs — |
| 47 | ENTRYPOINT CAPITAL, LLC | 309.0K +270.2K (+695.9%) | 389.4K +329.2K (+547.0%) | 0.04% +0.034 pp | 0.15% +0.129 pp | USD1.30 -3.1% | 2 qtrs — |
| 48 | CAPTION MANAGEMENT, LLC | 306.8K +— (+0.0%) | 386.6K -89.0K (-18.7%) | 0.04% -0.006 pp | 0.00% -0.001 pp | USD1.47 -14.3% | 6 qtrs — |
| 49 | MILLENNIUM MANAGEMENT LLC | 265.3K +265.3K (+100.0%) | 334.2K +334.2K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD1.26 +0.0% | 29 qtrs — |
| 50 | ROYAL BANK OF CANADA | 261.0K -11.8K (-4.3%) | 329.0K -94.0K (-22.2%) | 0.03% -0.007 pp | 0.00% +0.000 pp | USD2.43 -48.1% | 51 qtrs — |
| 51 | TUDOR INVESTMENT CORP ET AL | 244.8K +— (+0.0%) | 308.5K -71.0K (-18.7%) | 0.03% -0.005 pp | 0.00% 0.000 pp | USD2.00 -37.0% | 16 qtrs — |
| 52 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 229.6K -7.1K (-3.0%) | 289.3K -77.6K (-21.2%) | 0.03% -0.006 pp | 0.00% 0.000 pp | USD2.51 -49.8% | 51 qtrs — |
| 53 | JANUS HENDERSON GROUP PLC | 206.3K +— (+0.0%) | 258.9K -59.8K (-18.8%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD2.61 -51.7% | 18 qtrs — |
| 54 | BALYASNY ASSET MANAGEMENT L.P. | 198.8K +198.8K (+100.0%) | 250.5K +250.5K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 55 | MIRABELLA FINANCIAL SERVICES LLP | 193.7K +193.7K (+100.0%) | 244.1K +244.1K (+100.0%) | 0.02% +0.025 pp | 0.02% +0.023 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 56 | TWO SIGMA ADVISERS, LP | 191.2K -152.9K (-44.4%) | 240.9K -292.4K (-54.8%) | 0.02% -0.027 pp | 0.00% -0.001 pp | USD2.00 -37.0% | 20 qtrs — |
| 57 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 191.1K -82.0 (0.0%) | 240.8K -55.5K (-18.7%) | 0.02% -0.004 pp | 0.00% 0.000 pp | USD1.25 +0.8% | 7 qtrs — |
| 58 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 176.3K +— (+0.0%) | 222.1K -51.1K (-18.7%) | 0.02% -0.004 pp | 0.00% 0.000 pp | USD4.78 -73.6% | 51 qtrs — |
| 59 | METLIFE INVESTMENT MANAGEMENT, LLC | 175.7K -31.5K (-15.2%) | 221.4K -99.8K (-31.1%) | 0.02% -0.008 pp | 0.00% -0.001 pp | USD2.22 -43.2% | 31 qtrs — |
| 60 | GAMCO INVESTORS, INC. ET AL | 175.0K +— (+0.0%) | 220.5K -50.8K (-18.7%) | 0.02% -0.004 pp | 0.00% -0.001 pp | USD3.07 -59.0% | 64 qtrs — |
| 61 | GABELLI FUNDS LLC | 170.0K +— (+0.0%) | 214.2K -49.3K (-18.7%) | 0.02% -0.003 pp | 0.00% 0.000 pp | USD4.98 -74.7% | 64 qtrs — |
| 62 | INTECH INVESTMENT MANAGEMENT LLC | 159.7K +16.3K (+11.4%) | 201.2K -21.0K (-9.4%) | 0.02% -0.001 pp | 0.00% 0.000 pp | USD1.46 -13.7% | 6 qtrs — |
| 63 | IEQ CAPITAL, LLC | 157.8K -119.8K (-43.2%) | 198.8K -231.5K (-53.8%) | 0.02% -0.021 pp | 0.00% -0.001 pp | USD1.58 -20.3% | 5 qtrs — |
| 64 | PROSHARE ADVISORS LLC | 156.4K +86.0K (+122.2%) | 197.0K +87.9K (+80.6%) | 0.02% +0.010 pp | 0.00% +0.000 pp | USD1.92 -34.4% | 63 qtrs — |
| 65 | ZAZOVE ASSOCIATES LLC | 150.0K -57.6K (-27.7%) | 189.0K -132.8K (-41.3%) | 0.02% -0.012 pp | 0.02% -0.013 pp | USD1.66 -24.1% | 5 qtrs — |
| 66 | — | 140.0K -2.0K (-1.4%) | 176.4K -43.7K (-19.9%) | 0.02% -0.003 pp | 0.12% -0.013 pp | USD1.55 -18.7% | 2 qtrs — |
| 67 | VAN ECK ASSOCIATES CORP | 137.0K +25.2K (+22.5%) | 173.0K +— (+0.0%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD2.11 -40.3% | 15 qtrs — |
| 68 | QUANTBOT TECHNOLOGIES LP | 122.7K +122.7K (+100.0%) | 154.7K +154.7K (+100.0%) | 0.02% +0.016 pp | 0.01% +0.005 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 69 | COMERICA BANK | 120.0K +8.0K (+7.1%) | 151.2K -22.4K (-12.9%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD1.44 -12.5% | 10 qtrs — |
| 70 | GRAHAM CAPITAL MANAGEMENT, L.P. | 119.7K +21.3K (+21.6%) | 150.8K -1.7K (-1.1%) | 0.02% +0.001 pp | 0.00% +0.001 pp | USD1.57 -19.7% | 4 qtrs — |
| 71 | HIGHLINE WEALTH PARTNERS LLC | 116.7K +— (+0.0%) | 147.0K -33.8K (-18.7%) | 0.02% -0.002 pp | 0.04% -0.007 pp | USD1.91 -34.0% | 14 qtrs — |
| 72 | VIRTU FINANCIAL LLC | 115.3K +115.3K (+100.0%) | 145.0K +145.0K (+100.0%) | 0.01% +0.015 pp | 0.01% +0.006 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 73 | NEW YORK STATE COMMON RETIREMENT FUND | 114.3K -16.6K (-12.7%) | 144.0K -58.9K (-29.0%) | 0.01% -0.005 pp | 0.00% 0.000 pp | USD4.43 -71.6% | 47 qtrs — |
| 74 | ARIZONA STATE RETIREMENT SYSTEM | 113.8K -14.8K (-11.5%) | 143.4K -55.9K (-28.0%) | 0.01% -0.005 pp | 0.00% 0.000 pp | USD1.85 -31.9% | 24 qtrs — |
| 75 | GLENMEDE TRUST CO NA | 113.5K +113.5K (+100.0%) | 143.0K +143.0K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.001 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 76 | Y-INTERCEPT (HONG KONG) LTD | 112.9K +112.9K (+100.0%) | 142.3K +142.3K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.003 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 77 | SIH PARTNERS, LLLP | 104.3K -45.8K (-30.5%) | 131.5K -101.2K (-43.5%) | 0.01% -0.009 pp | 0.00% -0.004 pp | USD1.44 -12.5% | 3 qtrs — |
| 78 | QUBE RESEARCH & TECHNOLOGIES LTD | 102.8K +102.8K (+100.0%) | 129.5K +129.5K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 79 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 102.4K +— (+0.0%) | 129.0K -29.7K (-18.7%) | 0.01% -0.002 pp | 0.00% 0.000 pp | USD1.49 -15.4% | 5 qtrs — |
| 80 | RPG FAMILY WEALTH ADVISORY, LLC | 99.0K +— (+0.0%) | 124.7K -28.7K (-18.7%) | 0.01% -0.002 pp | 0.03% -0.006 pp | USD1.55 -18.7% | 2 qtrs — |
| 81 | AMERIPRISE FINANCIAL INC | 96.2K +1.0K (+1.1%) | 121.3K -26.4K (-17.9%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD1.82 -30.8% | 55 qtrs — |
| 82 | SIMPLEX TRADING, LLC | 93.9K -56.7K (-37.6%) | 118.3K -114.7K (-49.2%) | 0.01% -0.010 pp | 0.00% 0.000 pp | USD1.55 -18.7% | 2 qtrs — |
| 83 | SQUAREPOINT OPS LLC | 92.5K +— (+0.0%) | 116.6K -26.8K (-18.7%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD1.47 -14.3% | 5 qtrs — |
| 84 | QUADRATURE CAPITAL LTD | 91.7K +91.7K (+100.0%) | 115.5K +115.5K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.001 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 85 | KLP KAPITALFORVALTNING AS | 90.7K +16.7K (+22.6%) | 114.3K -418.0 (-0.4%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD1.43 -11.9% | 5 qtrs — |
| 86 | BNP PARIBAS ARBITRAGE, SNC | 90.4K -27.9K (-23.6%) | 113.9K -69.4K (-37.9%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD1.65 -23.6% | 51 qtrs — |
| 87 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 89.7K -6.8K (-7.0%) | 113.0K -37.0K (-24.7%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD7.76 -83.8% | 51 qtrs — |
| 88 | HEADLANDS TECHNOLOGIES LLC | 89.0K +43.7K (+96.6%) | 112.1K +42.0K (+59.9%) | 0.01% +0.005 pp | 0.01% +0.004 pp | USD1.45 -13.1% | 8 qtrs — |
| 89 | 360 FINANCIAL, INC. | 87.3K -4.0K (-4.4%) | 110.0K -31.5K (-22.3%) | 0.01% -0.002 pp | 0.03% -0.017 pp | USD1.82 -30.8% | 25 qtrs — |
| 90 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 85.3K +85.3K (+100.0%) | 107.5K +107.5K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.001 pp | USD1.26 +0.0% | 1 qtrs NEW |
| 91 | ADVISOR GROUP HOLDINGS, INC. | 75.3K -11.5K (-13.2%) | 94.9K -28.7K (-23.2%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD1.57 -19.7% | 24 qtrs — |
| 92 | CWM, LLC | 69.1K -55.6K (-44.6%) | 87.0K -106.0K (-54.9%) | 0.01% -0.010 pp | 0.00% 0.000 pp | USD1.57 -19.7% | 6 qtrs — |
| 93 | PENSIONMARK FINANCIAL GROUP, LLC | 66.5K +25.9K (+63.8%) | 83.8K +20.9K (+33.1%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD1.40 -10.0% | 6 qtrs — |
| 94 | CASCADE FINANCIAL PARTNERS, LLC | 66.5K +— (+0.0%) | 83.8K -19.3K (-18.7%) | 0.01% -0.001 pp | 0.01% -0.003 pp | USD1.31 -3.8% | 8 qtrs — |
| 95 | PICTET ASSET MANAGEMENT HOLDING SA | 65.5K +— (+0.0%) | 82.5K -19.0K (-18.7%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.60 -21.3% | 10 qtrs — |
| 96 | PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO | 61.5K +— (+0.0%) | 77.0K -18.0K (-18.9%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD13.21 -90.5% | 43 qtrs — |
| 97 | CETERA INVESTMENT ADVISERS | 59.2K +112.0 (+0.2%) | 74.5K -17.0K (-18.6%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.77 -28.8% | 21 qtrs — |
| 98 | CAPITAL ADVISORS INC/OK | 370.0K +— (+0.0%) | 25.3K -11.4K (-31.0%) | 0.05% -0.008 pp | 0.00% 0.000 pp | USD1.56 -19.2% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 78 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.46% | 101.4K | 0.20% |
| 2 | VanEck Israel ETF ISRA | 0.39% | 592.2K | 0.59% |
| 3 | State Street SPDR S&P Health Care Services ETF XHS | 0.36% | 723.0K | 0.35% |
| 4 | iShares U.S. Healthcare Providers ETF IHF | 0.09% | 1.05M | 0.38% |
| 5 | iShares MSCI USA Small-Cap Min Vol Factor ETF SMMV | 0.08% | 224.3K | 0.20% |
| 6 | iShares Ageing Population UCITS ETF AGED.L | 0.06% | 555.5K | 0.40% |
| 7 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.06% | 608.7K | 0.20% |
| 8 | iShares Biotechnology ETF IBB | 0.04% | 3.66M | 0.44% |
| 9 | Vanguard Russell 2000 Value ETF VTWV | 0.04% | 481.0K | 0.06% |
| 10 | iShares Russell 2000 Value ETF IWN | 0.04% | 5.11M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
60.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+60,000
Insider buys vs sells (history)
From
To
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-73.1K
Shares Outstanding
755.09M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | 480.0K | — | 400.0K | — | 14.0K | 1.85M | 21.57% | ↗ |
| 2 | 2025 | Elias A. Zerhouni, M.D. President | 900.0K | 450.0K | — | 400.0K | — | 14.0K | 1.76M | 22.68% | ↗ |
| 3 | 2025 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | 450.0K | — | 400.0K | — | 14.0K | 1.76M | 22.68% | ↗ |
| 4 | 2025 | Steven D. Rubin Executive Vice President- Administration | 810.0K | 400.0K | — | 350.0K | — | 14.0K | 1.57M | 22.24% | ↗ |
| 5 | 2025 | Adam Logal Senior Vice President and Chief Financial Officer | 700.0K | 475.0K | — | 350.0K | — | 14.0K | 1.54M | 22.74% | ↗ |
| 6 | 2024 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | 480.0K | 710.0K | — | — | 13.8K | 2.16M | 32.81% | ↗ |
| 7 | 2024 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | 450.0K | 710.0K | — | — | 13.8K | 2.07M | 34.24% | ↗ |
| 8 | 2024 | Elias A. Zerhouni, M.D. President | 900.0K | 450.0K | 710.0K | — | — | 13.8K | 2.07M | 34.24% | ↗ |
| 9 | 2024 | Steven D. Rubin Executive Vice President- Administration | 810.0K | 400.0K | 621.3K | — | — | 13.8K | 1.85M | 33.67% | ↗ |
| 10 | 2024 | Adam Logal Senior Vice President and Chief Financial Officer | 700.0K | 475.0K | 621.3K | — | — | 13.8K | 1.81M | 34.32% | ↗ |
| 11 | 2023 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | 480.0K | — | 824.0K | — | 13.2K | 2.28M | 36.18% | ↗ |
| 12 | 2023 | Elias A. Zerhouni, M.D. President | 900.0K | 450.0K | — | 824.0K | — | 13.2K | 2.19M | 37.67% | ↗ |
| 13 | 2023 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | 450.0K | — | 824.0K | — | 13.2K | 2.19M | 37.67% | ↗ |
| 14 | 2023 | Steven D. Rubin Executive Vice President- Administration | 810.0K | 400.0K | — | 721.0K | — | 13.2K | 1.94M | 37.08% | ↗ |
| 15 | 2023 | Adam Logal Senior Vice President and Chief Financial Officer | 700.0K | 375.0K | — | 721.0K | — | 13.2K | 1.81M | 39.85% | ↗ |
| 16 | 2022 | Jon R. Cohen, M.D. Former Senior Vice President OPKO Health, Inc.; Former Executive Chairman-BioReference Health, LLC | 600.0K | — | — | — | — | 1.01M | 1.61M | 0.00% | ↗ |
| 17 | 2022 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | — | — | 12.2K | 972.2K | 0.00% | ↗ |
| 18 | 2022 | Elias A. Zerhouni, M.D. President | 900.0K | — | — | 44.0K | — | 12.2K | 956.2K | 4.60% | ↗ |
| 19 | 2022 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | — | — | 12.2K | 912.2K | 0.00% | ↗ |
| 20 | 2022 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | — | — | 12.2K | 822.2K | 0.00% | ↗ |
| 21 | 2022 | Adam Logal Senior Vice President and Chief Financial Officer | 700.0K | — | — | — | — | 12.2K | 712.2K | 0.00% | ↗ |
| 22 | 2021 | Jon R. Cohen, M.D. Senior Vice President-OPKO OPKO Health, Inc.; Executive Chairman-BioReference Health, LLC | 575.0K | 1.15M | — | 1.70M | — | 11.6K | 3.43M | 49.44% | ↗ |
| 23 | 2021 | Jon R. Cohen, M.D. Former Senior Vice President OPKO Health, Inc.; Former Executive Chairman-BioReference Health, LLC | 575.0K | 1.15M | — | 1.70M | — | 11.6K | 3.43M | 49.44% | ↗ |
| 24 | 2021 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | 1.13M | — | 11.6K | 2.10M | 53.81% | ↗ |
| 25 | 2021 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | 1.13M | — | 11.6K | 2.04M | 55.39% | ↗ |
| 26 | 2021 | Adam Logal Senior Vice President and Chief Financial Officer | 700.0K | 200.0K | — | 990.5K | — | 11.6K | 1.90M | 52.07% | ↗ |
| 27 | 2021 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | 990.5K | — | 11.6K | 1.81M | 54.66% | ↗ |
| 28 | 2020 | Jon R. Cohen, M.D. Senior Vice President-OPKO OPKO Health, Inc.; Executive Chairman-BioReference Health, LLC | 575.0K | 1.15M | — | 1.76M | — | 11.2K | 3.49M | 50.27% | ↗ |
| 29 | 2020 | Jon R. Cohen, M.D. Former Senior Vice President OPKO Health, Inc.; Former Executive Chairman-BioReference Health, LLC | 575.0K | 1.15M | — | 1.76M | — | 11.2K | 3.49M | 50.27% | ↗ |
| 30 | 2020 | Jon R. Cohen, M.D. Senior Vice President-OPKO OPKO Health, Inc.; Executive Chairman-BioReference Laboratories, Inc. | 575.0K | 1.15M | — | 1.76M | — | 11.2K | 3.49M | 50.27% | ↗ |
| 31 | 2020 | Adam Logal Senior Vice President and Chief Financial Officer | 600.0K | 500.0K | — | 441.0K | — | 11.2K | 1.55M | 28.41% | ↗ |
| 32 | 2020 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | 567.0K | — | 11.2K | 1.54M | 36.86% | ↗ |
| 33 | 2020 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | 567.0K | — | 11.2K | 1.48M | 38.36% | ↗ |
| 34 | 2020 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | 441.0K | — | 11.2K | 1.26M | 34.94% | ↗ |
| 35 | 2019 | Jon R. Cohen, M.D. Senior Vice President-OPKO OPKO Health, Inc.; Executive Chairman-BioReference Health, LLC | 575.0K | 750.0K | — | 961.0K | — | 11.2K | 2.30M | 41.83% | ↗ |
| 36 | 2019 | Jon R. Cohen, M.D. Senior Vice President-OPKO OPKO Health, Inc.; Executive Chairman-BioReference Laboratories, Inc. | 575.0K | 750.0K | — | 961.0K | — | 11.2K | 2.30M | 41.83% | ↗ |
| 37 | 2019 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | 434.0K | — | 11.2K | 1.41M | 30.89% | ↗ |
| 38 | 2019 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | 434.0K | — | 11.2K | 1.35M | 32.26% | ↗ |
| 39 | 2019 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | 310.0K | — | 11.2K | 1.13M | 27.40% | ↗ |
| 40 | 2019 | Adam Logal Senior Vice President and Chief Financial Officer | 600.0K | — | — | 310.0K | — | 11.2K | 921.2K | 33.65% | ↗ |
| 41 | 2018 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | 1.07M | — | 11.0K | 2.04M | 52.31% | ↗ |
| 42 | 2018 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | 1.07M | — | 11.0K | 1.98M | 53.90% | ↗ |
| 43 | 2018 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | 639.0K | — | 11.0K | 1.46M | 43.77% | ↗ |
| 44 | 2018 | Adam Logal Senior Vice President and Chief Financial Officer | 600.0K | — | — | 639.0K | — | 11.0K | 1.25M | 51.12% | ↗ |
| 45 | 2017 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | — | — | 10.8K | 970.8K | 0.00% | ↗ |
| 46 | 2017 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | — | — | 15.8K | 915.8K | 0.00% | ↗ |
| 47 | 2017 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | — | — | 10.8K | 820.8K | 0.00% | ↗ |
| 48 | 2017 | Adam Logal Senior Vice President and Chief Financial Officer | 600.0K | — | — | — | — | 10.8K | 610.8K | 0.00% | ↗ |
| 49 | 2016 | Phillip Frost, M.D. Chief Executive Officer | 960.0K | — | — | 2.09M | — | 10.6K | 3.06M | 68.29% | ↗ |
| 50 | 2016 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 900.0K | — | — | 1.88M | — | 70.6K | 2.85M | 65.96% | ↗ |
| 51 | 2016 | Steven D. Rubin Executive Vice President-Administration | 810.0K | — | — | 1.88M | — | 10.6K | 2.70M | 69.63% | ↗ |
| 52 | 2016 | Steven D. Rubin Executive Vice President- Administration | 810.0K | — | — | 1.88M | — | 10.6K | 2.70M | 69.63% | ↗ |
| 53 | 2016 | Adam Logal Senior Vice President and Chief Financial Officer | 600.0K | — | — | 1.05M | — | 10.6K | 1.66M | 63.12% | ↗ |
| 54 | 2015 | Phillip Frost, M.D. Chief Executive Officer | 525.0K | 200.0K | — | 3.10M | — | 10.6K | 3.84M | 80.82% | ↗ |
| 55 | 2015 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 515.0K | 175.0K | — | 2.79M | — | 70.6K | 3.55M | 78.58% | ↗ |
| 56 | 2015 | Steven D. Rubin Executive Vice President- Administration | 504.0K | 150.0K | — | 2.79M | — | 10.6K | 3.45M | 80.76% | ↗ |
| 57 | 2015 | Steven D. Rubin Executive Vice President-Administration | 504.0K | 150.0K | — | 2.79M | — | 10.6K | 3.45M | 80.76% | ↗ |
| 58 | 2015 | Adam Logal Senior Vice President and Chief Financial Officer | 350.0K | 100.0K | — | 1.55M | — | 10.6K | 2.01M | 77.09% | ↗ |
| 59 | 2014 | Phillip Frost, M.D. Chief Executive Officer | 500.0K | — | — | 1.82M | — | 290.4K | 2.61M | 69.77% | ↗ |
| 60 | 2014 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 490.0K | — | — | 1.60M | — | 70.4K | 2.16M | 74.01% | ↗ |
| 61 | 2014 | Steven D. Rubin Executive Vice President- Administration | 480.0K | — | — | 1.60M | — | 10.4K | 2.09M | 76.48% | ↗ |
| 62 | 2014 | Steven D. Rubin Executive Vice President-Administration | 480.0K | — | — | 1.60M | — | 10.4K | 2.09M | 76.48% | ↗ |
| 63 | 2014 | Adam Logal Senior Vice President and Chief Financial Officer | 300.0K | — | — | 1.14M | — | 10.4K | 1.45M | 78.60% | ↗ |
| 64 | 2014 | Juan F. Rodriguez Former Senior Vice President and Chief Financial Officer | 74.0K | — | — | — | — | 102.6K | 176.6K | 0.00% | ↗ |
| 65 | 2013 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 482.3K | — | — | 1.77M | — | 240.2K | 2.50M | 71.05% | ↗ |
| 66 | 2013 | Phillip Frost, M.D. Chief Executive Officer | 492.3K | — | — | 1.97M | — | 10.2K | 2.47M | 79.68% | ↗ |
| 67 | 2013 | Steven D. Rubin Executive Vice President- Administration | 455.0K | — | — | 1.77M | — | 10.2K | 2.24M | 79.22% | ↗ |
| 68 | 2013 | Steven D. Rubin Executive Vice President-Administration | 455.0K | — | — | 1.77M | — | 10.2K | 2.24M | 79.22% | ↗ |
| 69 | 2013 | Juan F. Rodriguez Former Senior Vice President and Chief Financial Officer | 275.0K | — | — | — | — | 10.2K | 285.2K | 0.00% | ↗ |
| 70 | 2012 | Juan F. Rodriguez Former Senior Vice President and Chief Financial Officer | 127.0K | — | — | 711.0K | — | 4.6K | 842.6K | 84.38% | ↗ |
| 71 | 2012 | Phillip Frost, M.D. Chief Executive Officer | 460.0K | — | — | — | — | 9.8K | 469.8K | 0.00% | ↗ |
| 72 | 2012 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 450.0K | — | — | — | — | 9.8K | 459.8K | 0.00% | ↗ |
| 73 | 2012 | Steven D. Rubin Executive Vice President- Administration | 350.0K | — | — | — | — | 9.8K | 359.8K | 0.00% | ↗ |
| 74 | 2012 | Steven D. Rubin Executive Vice President-Administration | 350.0K | — | — | — | — | 9.8K | 359.8K | 0.00% | ↗ |
| 75 | 2011 | Phillip Frost, M.D. Chief Executive Officer | 460.0K | — | — | — | — | 9.8K | 469.8K | 0.00% | ↗ |
| 76 | 2011 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 450.0K | — | — | — | — | 9.8K | 459.8K | 0.00% | ↗ |
| 77 | 2011 | Steven D. Rubin Executive Vice President- Administration | 350.0K | — | — | — | — | 9.8K | 359.8K | 0.00% | ↗ |
| 78 | 2011 | Steven D. Rubin Executive Vice President-Administration | 350.0K | — | — | — | — | 9.8K | 359.8K | 0.00% | ↗ |
| 79 | 2011 | Rao Uppaluri, Ph.D. Senior Vice President and Chief Financial Officer | 310.0K | — | — | — | — | 9.8K | 319.8K | 0.00% | ↗ |
| 80 | 2010 | Phillip Frost, M.D. Chief Executive Officer | 439.2K | — | — | 642.5K | — | 9.8K | 1.09M | 58.86% | ↗ |
| 81 | 2010 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 426.9K | — | — | 642.5K | — | 9.8K | 1.08M | 59.53% | ↗ |
| 82 | 2010 | Steven D. Rubin Executive Vice President- Administration | 342.3K | — | — | 378.4K | — | 9.8K | 730.5K | 51.80% | ↗ |
| 83 | 2010 | Rao Uppaluri, Ph.D. Senior Vice President and Chief Financial Officer | 304.6K | — | — | 335.5K | — | 9.8K | 649.9K | 51.62% | ↗ |
| 84 | 2009 | Phillip Frost, M.D. Chief Executive Officer | 337.5K | — | — | 236.6K | — | 54.8K | 628.9K | 37.62% | ↗ |
| 85 | 2009 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 311.5K | — | — | 202.8K | — | 9.8K | 524.2K | 38.70% | ↗ |
| 86 | 2009 | Steven D. Rubin Executive Vice President- Administration | 311.5K | — | — | 169.0K | — | 9.8K | 490.4K | 34.47% | ↗ |
| 87 | 2009 | Rao Uppaluri, Ph.D. Senior Vice President and Chief Financial Officer | 285.6K | — | — | 152.1K | — | 9.8K | 447.5K | 33.99% | ↗ |
| 88 | 2008 | Steven D. Rubin Executive Vice President-Administration | 300.0K | — | — | 414.1K | — | 9.2K | 723.3K | 57.25% | ↗ |
| 89 | 2008 | Phillip Frost, M.D. Chief Executive Officer | 325.0K | — | — | 291.3K | — | 9.2K | 625.5K | 46.57% | ↗ |
| 90 | 2008 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 300.0K | — | — | 242.8K | — | 9.2K | 552.0K | 43.98% | ↗ |
| 91 | 2008 | Steven D. Rubin Executive Vice President- Administration | 300.0K | — | — | 194.2K | — | 9.2K | 503.4K | 38.58% | ↗ |
| 92 | 2008 | Rao Uppaluri, Ph.D. Senior Vice President and Chief Financial Officer | 275.0K | — | — | 169.9K | — | 9.2K | 454.1K | 37.42% | ↗ |
| 93 | 2008 | Naveed Shams, M.D., Ph.D. Senior Vice President- Research & Development and Chief Medical Officer | 259.1K | — | — | 71.4K | — | 25.8K | 356.4K | 20.04% | ↗ |
| 94 | 2007 | Phillip Frost, M.D. Chief Executive Officer | 208.3K | — | — | 3.02M | — | 133.3K | 3.36M | 89.84% | ↗ |
| 95 | 2007 | Dale R. Pfost Former President | 134.8K | 40.0K | — | — | — | 2.12M | 2.30M | 0.00% | ↗ |
| 96 | 2007 | Jane H. Hsiao, Ph.D. Chief Technical Officer | 192.3K | — | — | 1.96M | — | 7.7K | 2.16M | 90.76% | ↗ |
| 97 | 2007 | Steven D. Rubin Executive Vice President- Administration | 192.3K | — | — | 1.51M | — | 7.7K | 1.71M | 88.31% | ↗ |
| 98 | 2007 | Rao Uppaluri, Ph.D. Senior Vice President and Chief Financial Officer | 176.3K | — | — | 1.21M | — | 7.1K | 1.39M | 86.83% | ↗ |
| 99 | 2007 | Steven D. Rubin Executive Vice President-Administration | 192.3K | — | — | 251.8K | — | 7.7K | 451.3K | 55.79% | ↗ |
| 100 | 2007 | Adam Logal Executive Director of Finance, Chief Accounting Officer and Treasurer | 106.6K | 6.0K | — | 185.4K | — | — | 298.0K | 62.22% | ↗ |
| 101 | 2007 | John A. Paganelli Interim Chief Executive Officer | — | — | 96.5K | 59.8K | — | 2.5K | 158.8K | 98.43% | ↗ |
| 102 | 2006 | John A. Paganelli Interim Chief Executive Officer | 25.0K | — | — | 810.00 | — | 75.0K | 100.0K | 0.81% | ↗ |
| 103 | 2005 | David E. Riggs CEO, Former President, CFO and Secretary | 244.0K | — | — | — | — | — | 244.0K | 0.00% | ↗ |
| 104 | 2005 | John A. Paganelli, Interim CEO | 12.5K | — | — | 20.0K | — | 75.0K | 107.5K | 18.60% | ↗ |
| 105 | 2005 | Dr. David Hostelley, CFO | 15.0K | — | — | — | — | — | 15.0K | 0.00% | ↗ |
| 106 | 2004 | David E. Riggs Former President, CFO | 235.0K | — | — | 75.0K | — | — | 310.0K | 24.19% | ↗ |
| 107 | 2004 | David E. Riggs CEO, Former President, CFO and Secretary | 235.0K | — | — | 75.0K | — | — | 310.0K | 24.19% | ↗ |
| 108 | 2004 | Ronald L. Goode, Ph.D. Former President, CEO | 95.8K | — | — | — | — | — | 95.8K | 0.00% | ↗ |
| 109 | 2004 | John A. Paganelli, Interim CEO | — | — | — | 20.0K | — | 75.0K | 95.0K | 21.05% | ↗ |
| 110 | 2003 | Ronald L. Goode, Ph.D. former President, CEO | 405.0K | 105.0K | — | — | — | 12.0K | 522.0K | 0.00% | ↗ |
| 111 | 2003 | Ronald L. Goode, Ph.D. Former President, CEO | 405.0K | 105.0K | — | — | — | 12.0K | 522.0K | 0.00% | ↗ |
| 112 | 2003 | Ronald L. Goode, Ph.D former President, CEO | 405.0K | 105.0K | — | — | — | 1.00 | 510.0K | 0.00% | ↗ |
| 113 | 2003 | David E. Riggs Vice President, Chief Business Officer, Chief Financial Officer & Secretary | 190.6K | — | — | 225.0K | — | — | 415.6K | 54.14% | ↗ |
| 114 | 2003 | David E. Riggs CEO, Former President, CFO and Secretary | 190.6K | — | — | 225.0K | — | — | 415.6K | 54.14% | ↗ |
| 115 | 2003 | David E. Riggs Former President, CFO | 190.6K | — | — | 225.0K | — | — | 415.6K | 54.14% | ↗ |
| 116 | 2002 | Ronald L. Goode, Ph.D. former President, CEO | 373.3K | 105.0K | — | 300.0K | — | 12.0K | 790.3K | 37.96% | ↗ |
| 117 | 2002 | Ronald L. Goode, Ph.D former President, CEO | 373.3K | 105.0K | — | 300.0K | — | 1.00 | 778.3K | 38.54% | ↗ |
| 118 | 2001 | Ronald L. Goode, Ph.D. former President, CEO | 275.5K | — | — | 400.0K | — | 81.3K | 756.8K | 52.85% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Phillip Frost | Chairman of the Board & CEO | 1M | — |
| Elias Adam Zerhouni | President & Vice Chairman of the Board | 1M | — |
| Jane H. Hsiao | Vice Chairman of the Board & Chief Technical Officer | 1M | — |
| Steven D. Rubin | Executive Vice President of Administration & Director | 1M | male |
| Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer | 1M | male |
| Damien Burke | Chief Executive Officer of EirGen Pharma | — | male |
| Craig Allen | Chief Executive Officer of Bioreference Health | — | male |
| Gary J. Nabel | Chief Information Officer & Director | — | — |
| Giovanni Abbadessa | Chief Medical Officer of ModeX | — | male |
| Hans Berner | President of OPKO Health Iberoamerica | — | male |
| Charles W. Bishop | Chief Executive Officer of OPKO Renal | — | — |
| John R. Mascola | Chief Scientific Officer of ModeX | — | — |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OPK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
